Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

Abstract

Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo. (Funded by Gilead Sciences; PINETREE ClinicalTrials.gov number, NCT04501952; EudraCT number, 2020-003510-12.).

Keywords

Affiliated Institutions

• University College London Hospitals NHS Foundation Trust GB
• Gilead Sciences (United States) US
• Brigham and Women's Hospital US
• Harvard University US
• Hospital General Universitario Gregorio Marañón ES
• Copenhagen University Hospital DK
• University of Utah US
• London School of Hygiene & Tropical Medicine GB
• Johns Hopkins Medicine US
• University College London GB
• Baylor Medical Center at Garland US
• Intermountain Healthcare US
• IrsiCaixa ES
• Institute for Liver Health US
• Rigshospitalet DK
• Hospital Universitari Germans Trias i Pujol ES
• Baylor University Medical Center US
• Orlando Clinical Research Center US
• Hospital Universitario Infanta Leonor ES
• Fred Hutch Cancer Center US
• Meridien Research US
• University of Colorado Denver US
• Triple O Medical Services US
• Johns Hopkins University US
• University of Washington US
• Kaiser Permanente Oakland Medical Center US
• Cherokee Nation US

Related Publications